TPST-1495 twice daily + TPST-1495 once daily or on intermittent schedule + Pembrolizumab
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Tumor
Conditions
Solid Tumor, Colorectal Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Endometrial Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma, Solid Tumors With PIK3Ca Mutation
Trial Timeline
May 6, 2020 → Sep 25, 2024
NCT ID
NCT04344795About TPST-1495 twice daily + TPST-1495 once daily or on intermittent schedule + Pembrolizumab
TPST-1495 twice daily + TPST-1495 once daily or on intermittent schedule + Pembrolizumab is a phase 1 stage product being developed by Tempest Therapeutics for Solid Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT04344795. Target conditions include Solid Tumor, Colorectal Cancer, Non Small Cell Lung Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04344795 | Phase 1 | Completed |
Competing Products
20 competing products in Solid Tumor